People who receive stem cell therapy within a week of their first heart attack have nearly a 60 per cent lower risk of ...
Tribune Online on MSN
Timely diagnosis and treatment of congestive heart failure will prevent sudden deaths — Prof Opadijo, Consultant Cardiologist
The immediate past Chief Medical Director of LAUTECH Teaching Hospital, Ogbomoso, Oyo State, Prof. O. G. Opadijo, is a consultant cardiologist and expert in cardiology medicine. In this interview by ...
HealthDay on MSN
FDA Approves At-Home Version of Lasix for Heart Failure Care
The U.S. Food and Drug Administration (FDA) has approved Lasix ONYU (furosemide injection), a new drug-device combination developed by SQ Innovation, Inc., for treating edema caused by chronic heart ...
A new at-home version of a common heart failure drug could make treatment easier for millions of Americans. The U.S. Food and Drug Administration (FDA) has approved Lasix ONYU (furosemide injection), ...
The American College of Cardiology is launching a new program to educate clinicians on the latest advances, medications and interventions emerging in heart failure (HF) management and treatment.
The congestive heart failure market is projected to witness substantial growth driven by rising prevalence, technological advancements, and innovative treatment options. Key pharmaceutical companies, ...
Strengthened Global IP Portfolio: This registration extends Hemostemix's "Know Your Health" brand protection into Japan, one of the world's leading medical-research markets, further securing its ...
10d
New Drug Could “Un-Stiffen” Aging Hearts, Offering Hope for the Most Common Form of Heart Failure
A new experimental therapy helps restore the heart’s flexibility in models of stiffened heart failure. Michael Gotthardt and his colleagues at the Max Delbrück Center are working with U.S. researchers ...
A new drug being trialed in heart attack patients could reprogram the immune system to prevent inflammation and heart damage ...
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering VesCell™ ...
A research trial spearheaded by Merck hopes to change that — and Franciscan Health Indianapolis is at the forefront too, as it is the only hospital in Indiana selected to take part in the ...
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering VesCell™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback